- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arvinas Inc (ARVN)
Arvinas Inc stock price live, this page displays NASDAQ ARVN stock exchange data. View the ARVN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Arvinas Inc real time stock price chart below.
What Is the Arvinas Inc Stock Price Today?
The Arvinas Inc stock price today is 7.76.
What Is the Stock Symbol for Arvinas Inc?
The stock symbol for Arvinas Inc is ""ARVN.""
What Stock Exchange Does Arvinas Inc Trade On?
Arvinas Inc is listed and trades on the NASDAQ stock exchange.
Is Arvinas Inc a Good Stock to Buy?
Determining whether Arvinas Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARVN quote. (ISIN: US04335A1051)
What Is the Arvinas Inc Stock Price Today?
The Arvinas Inc stock price today is 7.76.
What Is the Stock Symbol for Arvinas Inc?
The stock symbol for Arvinas Inc is ""ARVN.""
What Stock Exchange Does Arvinas Inc Trade On?
Arvinas Inc is listed and trades on the NASDAQ stock exchange.
Is Arvinas Inc a Good Stock to Buy?
Determining whether Arvinas Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARVN quote. (ISIN: US04335A1051)
NASDAQ
Currency in USD
Fair Value
An estimate of a Arvinas's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.75
8.22
52 wk Range
5.90
29.61
ARVN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ARVN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Arvinas's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.758.22
52 wk Range
5.9029.61
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ARVN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Arvinas's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
18.44
Upside
+137.69%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
10 analysts have revised their earnings upwards for the upcoming period
- Arvinas Holding receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Arvinas Holding receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Arvinas Holding receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Arvinas Inc Company Profile
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company’s products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Arvinas Inc SWOT Analysis
Vepdegestrant's Promise | Explore vepdegestrant's potential as a first-in-class oral PROTAC for ESR1-mutant breast cancer patients, with promising efficacy in recent trials |
Financial Crossroads | Delve into Arvinas's strategic restructuring and financial outlook, balancing cost-cutting measures with a healthy cash position and extended runway |
Market Dynamics | Learn about the challenges Arvinas faces in the competitive oral SERD market, with analyst price targets ranging from $10 to $48 |
Platform Potential | Discover the broader implications of Arvinas's PROTAC platform technology, offering opportunities beyond vepdegestrant in addressing "undruggable" proteins |
Arvinas Inc Earnings Call Summary for Q2/2025
- Q2 2025 EPS beat at -$0.84 vs -$0.94 forecast, but revenue missed at $22.4M vs $34.42M expected
- Stock dropped 10.96% post-earnings to $6.78; further 3.42% decline in pre-market trading
- Cost-cutting measures extended cash runway into 2028; R&D expenses reduced from $93.7M to $68.6M
- Advancing clinical programs including NDA submission for Vepdeg; seeking new partner for collaboration
- CEO transition ongoing; company focusing on neuroscience and oncology pipeline development
Last Updated: 06/08/2025, 14:50
Read Full TranscriptCompare ARVN to Peers and Sector
Metrics to compare | ARVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARVNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.8x | −2.9x | −0.6x | |
PEG Ratio | −0.10 | 0.21 | 0.00 | |
Price/Book | 0.9x | 2.8x | 2.6x | |
Price / LTM Sales | 1.5x | 1.8x | 3.3x | |
Upside (Analyst Target) | 86.9% | 113.6% | 39.1% | |
Fair Value Upside | Unlock | 12.9% | 5.4% | Unlock |
Analyst Ratings
12 Buy
9 Hold
0 Sell
Ratings:
21 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 18.44
(+137.69% Upside)
Earnings
Latest Release
Aug 06, 2025
EPS / Forecast
-0.84 / -0.94
Revenue / Forecast
22.40M / 34.42M
People Also Watch
FAQ
What Stock Exchange Does Arvinas Trade On?
Arvinas is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Arvinas?
The stock symbol for Arvinas is "ARVN."
What Is the Arvinas Market Cap?
As of today, Arvinas market cap is 571.19M.
What Is Arvinas's Earnings Per Share (TTM)?
The Arvinas EPS (TTM) is -1.00.
When Is the Next Arvinas Earnings Date?
Arvinas will release its next earnings report on 10 Nov 2025.
From a Technical Analysis Perspective, Is ARVN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Arvinas Stock Split?
Arvinas has split 0 times.
How Many Employees Does Arvinas Have?
Arvinas has 430 employees.
What is the current trading status of Arvinas (ARVN)?
As of 29 Aug 2025, Arvinas (ARVN) is trading at a price of 7.76, with a previous close of 8.08. The stock has fluctuated within a day range of 7.75 to 8.22, while its 52-week range spans from 5.90 to 29.61.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.